

## Decision Letter Solomon Islands Support for Rotavirus Vaccine

This Decision Letter sets out the terms of a Programme

<b>1. Country:</b> Solomon Islands				
<b>2. Grant number:</b> 1921-SLB-13b-X / 19-SLB-08b-Y				
<b>3. Date of Decision Letter:</b> 9 July 2018				
<b>4. Date of the Partnership Framework Agreement (PFA):</b> 29 April 2013				
<b>5. Programme title:</b> New Vaccine Support (NVS), Rotavirus routine				
<b>6. Vaccine type:</b> Rotavirus				
<b>7. Requested product presentation and formulation of vaccine:</b> Rotavirus, 2 dose(s) schedule				
<b>8. Programme duration<sup>1</sup>:</b> 2019 - 2021				
<b>9. Programme Budget (indicative):</b> (subject to the terms of the PFA, if applicable)				
	<b>2019</b>	2020	2021	Total <sup>2</sup>
Programme Budget (US\$)	88,500	59,000	40,500	188,000
<b>10. Vaccine introduction grant (in US\$):</b> 100,000 (in 2019), payable up to six months before the vaccine introduction.				
<b>11. Product switch grant:</b> Not applicable				
<b>12. Indicative Annual Amounts:</b> (subject to the terms of the PFA, if applicable) <sup>3</sup>				
Type of supplies to be purchased with Gavi funds in each year				2019
Number of Rotavirus vaccines doses				37,500
Annual Amounts (US\$)				88,500
<b>13. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.				
<b>14. Self-procurement:</b> Not applicable				

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the amount that Gavi has approved.

**15. Co-financing obligations:** Reference code: 1921-SLB-13b-X-C

According to the co-financing policy, the Country falls within the group accelerated transition as of 2017. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2019	2020	2021
Number of vaccine doses	10,500	18,000	25,500
Number of AD syringes	0	0	0
Number of re-constitution syringes	0	0	0
Number of safety boxes	0	0	0
Value of vaccine doses (US\$)	22,250	37,582	55,694
Total co-financing payments (US\$) (including freight)	23,000	39,000	57,500

**16. Operational support for campaigns:** Not applicable

**17. Additional reporting requirements:**

Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts.

Requirements	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

**18. Financial clarifications:** Not applicable

**19. Other conditions:** Not applicable

Signed by,



**On behalf of Gavi**

Hind Khatib-Othman  
 Managing Director, Country Programmes  
 9 July 2018